Novel compositions which inhibit melanogenesis and uses thereof

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 8/60 (2006.01) A61K 8/73 (2006.01) A61K 31/7088 (2006.01) A61K 31/7105 (2006.01) A61P 17/00 (2006.01) A61Q 19/02 (2006.01) C12N 15/11 (2006.01)

Patent

CA 2720664

The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a subunit of the AP-1 adaptor complex, of a kinesin which interacts with AP-1, in particular Kif13A, or of the interaction between a subunit of the AP-1 adaptor complex and said kinesin, and also to the use thereof for the manufacture of a medicament for use in the treatment of pigmentary disorders and as a depigmenting agent.

La présente invention concerne de nouvelles compositions pharmaceutiques ou cosmétiques comprenant au moins un inhibiteur d'une sous-unité du complexe adaptateur AP-1, d'une kinésine interagissant avec AP-1, en particulier Kif13A, ou de l'interaction entre une sous-unité du complexe adaptateur AP-1 et ladite kinésine, ainsi que leur utilisation pour la fabrication d'un médicament destiné au traitement de troubles pigmentaire et comme agent dépigmentant.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Novel compositions which inhibit melanogenesis and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel compositions which inhibit melanogenesis and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel compositions which inhibit melanogenesis and uses thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1505284

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.